Engineering Papers⌕ Search

Engineering topics

Xu, Allison

Publications and source records attributed to Xu, Allison.

Generative machine learning for detector response modeling with a conditional normalizing flow

In this paper, we explore the potential of generative machine learning models as an alternative to the computationally expensive Monte Carlo (MC) simulations commonly used by the Large Hadron Collider (LHC) experiments. Our objective is to develop a generative model capable of efficiently simulating detector responses for specific particle observables, focusing on the correlations between detector responses of different particles in the same event and accommodating asymmetric detector responses. Here, we present a conditional normalizing flow model ($\mathcal{CNF}$) based on a chain of Masked Autoregressive Flows, which effectively incorporates conditional variables and models high-dimensional density distributions. We assess the performance of the $\mathcal{CNF}$ model using a simulated sample of Higgs boson decaying to diphoton events at the LHC. We create reconstruction-level observables using a smearing technique. We show that conditional normalizing flows can accurately model complex detector responses and their correlation. This method can potentially reduce the computational burden associated with generating large numbers of simulated events while ensuring that the generated events meet the requirements for data analyses. We make our code available at https://github.com/allixu/normalizing_flow_for_detector_response

46 INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND ↗

Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab

4-1BB (CD137, TNFRSF9) is an inducible costimulatory receptor expressed on activated T cells. Clinical trials of two agonist antibodies, utomilumab (PF-05082566) and urelumab (BMS-663513), are ongoing in multiple cancer indications, and both antibodies demonstrate distinct activities in the clinic. To understand these differences, we solved structures of the human 4-1BB/4-1BBL complex, the 4-1BBL trimer alone, and 4-1BB bound to utomilumab or urelumab. The 4-1BB/4-1BBL complex displays a unique interaction between receptor and ligand when compared with other TNF family members. Furthermore, our ligand-only structure differs from previously published data. Utomilumab, a ligand-blocking antibody, binds 4-1BB between CRDs 3 and 4. In contrast, urelumab binds 4-1BB CRD-1, away from the ligand binding site. Finally, cell-based assays demonstrate utomilumab is a milder agonist than urelumab. Collectively, our data provide a deeper understanding of the 4-1BB signaling complex, providing a template for future development of next generation 4-1BB targeted biologics.

Science & Technology - Other Topics↗